Affimed N.V. is a biopharmaceutical company focused on developing cancer immunotherapies for advanced cancers. Its lead product candidate, AFM13, is currently being studied in clinical trials for Hodgkin lymphoma and other malignant diseases. Affimed N.V. is located in Heidelberg, Germany, and has research partnerships with several established pharmaceutical companies and research organizations.